First Onset of IgA Vasculitis and Nephritis Following COVID-19 Vaccination

The article presents a case of a 32-year-old male who developed IgA vasculitis (IgAV) and IgA vasculitis nephritis (IgAVN) after receiving the second dose of the AstraZeneca COVID-19 vaccine. IgAVN can be a rare side effect of COVID-19 vaccines. Healthcare providers should be aware of this potential...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Ortega, Jesús Iván, Perez-Hernandez, Felipe, Fernández-Reyna, Ilse, Eljure Lopez, Nixma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449366/
https://www.ncbi.nlm.nih.gov/pubmed/37637560
http://dx.doi.org/10.7759/cureus.42448
Descripción
Sumario:The article presents a case of a 32-year-old male who developed IgA vasculitis (IgAV) and IgA vasculitis nephritis (IgAVN) after receiving the second dose of the AstraZeneca COVID-19 vaccine. IgAVN can be a rare side effect of COVID-19 vaccines. Healthcare providers should be aware of this potential adverse event, and promptly recognize and manage it. However, the benefits of vaccination in reducing the morbidity and mortality associated with COVID-19 far outweigh the risks of this rare adverse event.

Ejemplares similares